- Home
- ELLO vs ALT Comparison
ELLO vs ALT Comparison
Compare ELLO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELLO | ALT |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.7M | 415.3M |
| IPO Year | 1998 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ELLO | ALT |
|---|---|---|
| Price | $25.28 | $3.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 2.2K | ★ 2.9M |
| Earning Date | 12-30-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $13.00 | $2.91 |
| 52 Week High | $30.34 | $7.73 |
Technical Indicators
Market Signals| Indicator | ELLO | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 36.46 |
| Support Level | $24.21 | $3.40 |
| Resistance Level | $28.71 | $4.25 |
| Average True Range (ATR) | 0.76 | 0.24 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 28.40 | 13.94 |
Price Performance
Historical ComparisonAbout ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.